EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Edwards Lifesciences Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$87.22+0.62 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $50.38B
- P/E (TTM)
- 50.1
- Dividend yield
- –
Edwards Lifesciences Corp revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.54B | $3.21B | $2.95B | $2.63B | $2.96B | $2.52B | $2.53B | $2.06B | $1.91B | $1.62B | 58.4% | +10.5% |
| Europe | $1.52B | $1.32B | $1.18B | $1.04B | $1.10B | $945.20M | $926.10M | $826.40M | $800.70M | $745.90M | 25.0% | +14.8% |
| Rest of World | $652.30M | $572.00M | $531.10M | $436.00M | $533.20M | $451.50M | $433.30M | $396.00M | $357.30M | $303.60M | 10.8% | +14.0% |
| Japan | $354.70M | $339.80M | $350.80M | $359.50M | $528.00M | $448.60M | $441.40M | $398.40M | $356.50M | $279.60M | 5.8% | +4.4% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $4.49B | $4.11B | $3.88B | $3.52B | $3.42B | $2.86B | $2.74B | $2.28B | – | – | 74.0% | +9.3% |
| Surgical Structural Heart | $1.03B | $981.30M | $932.60M | $829.70M | $889.10M | $761.80M | $841.70M | $761.60M | $807.10M | $774.90M | 17.0% | +4.9% |
| Transcatheter Mitral and Tricuspid Therapies | $550.60M | $352.10M | $197.60M | $116.10M | $86.00M | $41.80M | $28.20M | $2.90M | $3.40M | – | 9.1% | +56.4% |
| Critical Care | – | – | $928.10M | $855.00M | $834.90M | $725.40M | $740.20M | $674.50M | $601.00M | $560.30M | – | – |
| Transcatheter Aortic Valve Replacement | – | – | – | – | – | – | $2.74B | $2.28B | $2.02B | $1.63B | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | $3.51B | $3.13B | $2.96B | $2.52B | $2.53B | $2.06B | $1.91B | $1.62B | – | – |
| Europe | – | – | $1.33B | $1.17B | $1.19B | $973.60M | $941.20M | $885.10M | $831.00M | $749.00M | – | – |
| Japan | – | – | $452.40M | $473.60M | $528.90M | $460.10M | $444.70M | $396.80M | $350.30M | $309.30M | – | – |
| Rest of World | – | – | $709.20M | $601.40M | $550.20M | $435.80M | $429.40M | $385.60M | $346.40M | $289.70M | – | – |
From the segment and revenue-disaggregation notes of Edwards Lifesciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.